BiomX outlines imminent FDA feedback and targets BX004 Phase IIb data in Q1 2026 while advancing BX011 for diabetic foot infections

Q3 2025 Management View Jonathan Solomon, CEO, stated that the third quarter of 2025 was an important period for BiomX, ...